Posted by Michael Wonder on 02 Apr 2024
Merck’s superovulation induction drug Pergoveris gets expanded coverage
1 April 2024 - Merck Biopharma Korea's superovulation induction injection Pergoveris (follitropin alfa) will receive expanded reimbursement to treat patients with severe luteinizing hormone (LH) and follicle-stimulating hormone deficiencies from Monday.
The change in reimbursement criteria expands the current coverage for Pergoveris from "up to two vials/day for assisted reproduction in patients with severe endogenous serum luteinizing hormone (LH) deficiency (concentration < 1.2 IU/L)" to "up to two vials/day for assisted reproduction in patients with LH deficiency.
